preclinical_heavy
Preclinical evidence exceeds central human evidence. Interpret translational relevance cautiously.
supportedtophigh inflation risk
Bifidobacterium
inflammatory bowel disease
Bifidobacterium has meaningful literature visibility in inflammatory bowel disease, but the current evidence mix suggests a substantial risk of overclaiming.
Bifidobacterium shows a moderate evidence base in inflammatory bowel disease, with multiple central papers and additional supporting literature.
bifidobacterium
Credibility score
45
Human translation
2/5
Reproducibility
5/5
Novelty
2/5
Actionability
2/5
Credibility 45Human translation 2/5Reproducibility 5/5Novelty 2/5Actionability 2/5
Why this scores the way it does
- moderate central evidence base
- dense review literature
- substantial preclinical support
Main caveats
- preclinical evidence outweighs human evidence
- review density exceeds central evidence depth
Internal review flags
2 flagsreview_heavy
Review literature is very dense relative to primary central evidence.
Primary central evidence
8 papersFecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation.
2015The American journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial.
2020Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal microbiota profile in patients with inflammatory bowel disease in Taiwan.
2021Journal of the Chinese Medical Association : JCMA
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Colon-Targeted Adhesive Hydrogel Microsphere for Regulation of Gut Immunity and Flora.
2021Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease.
2024Nature communications
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Amelioration of inflammatory bowel disease by Bifidobacterium animalis subsp. lactis XLTG11 in combination with mesalazine.
2024Frontiers in microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Culture-based characterization of gut microbiota in inflammatory bowel disease.
2025Frontiers in microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal microbial and metabolic signatures in children with very early onset inflammatory bowel disease.
2025NPJ biofilms and microbiomes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
16 papersTriclocarban exposure exaggerates colitis and colon tumorigenesis: roles of gut microbiota involved.
2020Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
B. adolescentis ameliorates chronic colitis by regulating Treg/Th2 response and gut microbiota remodeling.
2021Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bifidobacterium BLa80 mitigates colitis by altering gut microbiota and alleviating inflammation.
2022AMB Express
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Artificial-enzymes-armed Bifidobacterium longum probiotics for alleviating intestinal inflammation and microbiota dysbiosis.
2023Nature nanotechnology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bifidobacterium and Lactobacillus improve inflammatory bowel disease in zebrafish of different ages by regulating the intestinal mucosal barrier and microbiota.
2023Life sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bifidobacterium animalis subsp. lactis LKM512 Alleviates Inflammatory Bowel Disease in Larval Zebrafish by Reshaping Microbiota.
2023Biological & pharmaceutical bulletin
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Reverse metabolomics for the discovery of chemical structures from humans.
2024Nature
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Indole-3-acetic acid alleviates DSS-induced colitis by promoting the production of R-equol from Bifidobacterium pseudolongum.
2024Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut virome-wide association analysis identifies cross-population viral signatures for inflammatory bowel disease.
2024Microbiome
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Roseburia intestinalis-derived extracellular vesicles ameliorate colitis by modulating intestinal barrier, microbiome, and inflammatory responses.
2024Journal of extracellular vesicles
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Dehydroevodiamine Alleviates Ulcerative Colitis by Inhibiting the PI3K/AKT/NF-κB Signaling Pathway via Targeting AKT1 and Regulating Gut Microbes and Serum Metabolism.
2024Molecules (Basel, Switzerland)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bifidobacterium pseudolongum-Derived Bile Acid from Dietary Carvacrol and Thymol Supplementation Attenuates Colitis via cGMP-PKG-mTORC1 Pathway.
2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal Extracts in an In Vitro Model of Intestinal Epithelial Barrier Dysfunction.
2024The Yale journal of biology and medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Characteristics of the gut microbiota and the effect of Bifidobacterium in very early-onset inflammatory bowel disease patients with IL10RA mutations.
2024Frontiers in microbiology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
3'-Sialyllactose and B. infantis synergistically alleviate gut inflammation and barrier dysfunction by enriching cross-feeding bacteria for short-chain fatty acid biosynthesis.
2025Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Akkermansia muciniphila-derived extracellular vesicles alleviate colitis-related cognitive impairment via tryptophan metabolic reprogramming of the gut‒brain axis.
2026Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
24 papersHost-bacterial interactions in inflammatory bowel disease.
2004Clinical science (London, England : 1979)
Relevant review or meta-analysis for the signal-disease area.
Probiotics and the management of inflammatory bowel disease.
2004Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.
2008British journal of clinical pharmacology
Relevant review or meta-analysis for the signal-disease area.
Probiotics.
2009Indian journal of medical microbiology
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota and pediatric disease.
2011Digestive diseases (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
Probiotics: an update.
2015Jornal de pediatria
Relevant review or meta-analysis for the signal-disease area.
The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials.
2015BioMed research international
Relevant review or meta-analysis for the signal-disease area.
Using murine colitis models to analyze probiotics-host interactions.
2017FEMS microbiology reviews
Relevant review or meta-analysis for the signal-disease area.
Probiotics and Their Use in Inflammatory Bowel Disease.
2018Alternative therapies in health and medicine
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiome: Profound Implications for Diet and Disease.
2019Nutrients
Relevant review or meta-analysis for the signal-disease area.
Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences.
2019United European gastroenterology journal
Relevant review or meta-analysis for the signal-disease area.
Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis.
2021European journal of nutrition
Relevant review or meta-analysis for the signal-disease area.
Repeated Fecal Microbial Transplantations and Antibiotic Pre-Treatment Are Linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: A Systematic Review and Pooled Proportion Meta-Analysis.
2021Journal of clinical medicine
Relevant review or meta-analysis for the signal-disease area.
Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis.
2021International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Bifidobacterium Longum: Protection against Inflammatory Bowel Disease.
2021Journal of immunology research
Relevant review or meta-analysis for the signal-disease area.
Causal Relationship Between Gut Microbiota and Autoimmune Diseases: A Two-Sample Mendelian Randomization Study.
2021Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.
Adrenomedullin: Not Just Another Gastrointestinal Peptide.
2022Biomolecules
Relevant review or meta-analysis for the signal-disease area.
Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives.
2023World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
A review on the use of prebiotics in ulcerative colitis.
2024Trends in microbiology
Relevant review or meta-analysis for the signal-disease area.
Probiotics for inflammatory bowel disease: Is there sufficient evidence?
2024Open life sciences
Relevant review or meta-analysis for the signal-disease area.
Exploration of the Muribaculaceae Family in the Gut Microbiota: Diversity, Metabolism, and Function.
2024Nutrients
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota mediated T cells regulation and autoimmune diseases.
2024Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
Microbiota and inflammatory bowel disease: the dual effect mechanism of polysaccharide therapy.
2025Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.
Probiotics and the intestinal tight junction barrier function.
2025Frontiers in cell and developmental biology
Relevant review or meta-analysis for the signal-disease area.